Vania Modesto-Lowe, MD, MPH

Hartford Behavioral Health, Hartford, Connecticut; Department of Psychiatry, University of Connecticut, Farmington, Connecticut; School of Health Sciences, Quinnipiac University, Hamden, Connecticut; Corresponding Author: Vania Modesto-Lowe, MD, MPH, Hartford Behavioral Health, 2550 Main St, Hartford, CT 06120 ([email protected]).

Smartphone Applications: Therapy at Your Fingertips

Letter to the Editor

Smartphone Applications: Therapy at Your Fingertips

August 20, 2024

The authors discuss the advancements in smartphone applications for psychiatry, as well as some of the risks.

Vania Modesto-Lowe, Sofia Adams, Amanda Rossi

Zeroing in on Xylazine

Letter to the Editor

Zeroing in on Xylazine

August 15, 2024

The authors discuss the need to raise awareness among US public and health care professionals about xylazine due to its infiltration into the illicit drug supply.

Jasleen Kaur, Megan Nosol, Vania Modesto-Lowe

Fentanyl Test Strips and Drug Use Modification

Letter to the Editor

Fentanyl Test Strips and Drug Use Modification

May 14, 2024

The authors explore the use of fentanyl test strips as a harm reduction tactic to identify contaminated substances for people who use illicit drugs.

Vania Modesto-Lowe, Robyn Roznitsky, Kiana Caitlin Tan

Do Not Overlook Bupropion Misuse

Letter to the Editor

Do Not Overlook Bupropion Misuse

April 30, 2024

Jasleen Kaur, MD, and colleagues comment on a case report published in the PCC.

Jasleen Kaur, Vania Modesto-Lowe, Roberto León-Barriera

Deprescribing Benzodiazepines: Is Harm Reduction Enough?

Letter to the Editor

Deprescribing Benzodiazepines: Is Harm Reduction Enough?

December 28, 2023

Vania Modesto-Lowe, MD, MPH, and Claire N. Aurilio, BS, comment on a recent publication in the PCC.

Vania Modesto-Lowe, Claire N. Aurilio

Social Determinants of Health and Extended-Release Naltrexone

Brief Report

Social Determinants of Health and Extended-Release Naltrexone

June 29, 2023

Patients with alcohol use disorder are at high risk of treatment nonadherence and readmission. While ER naltrexone can help prevent relapse for 28 days, they may face homelessness for...

Lakshit Jain, Vania Modesto-Lowe

Buprenorphine Maintenance in the Fentanyl Era

Letter to the Editor

Buprenorphine Maintenance in the Fentanyl Era

February 14, 2023

Methods to foster patient adherence and physician acceptability of buprenorphine maintenance are needed to incorporate this treatment into primary care for fentanyl users.

Vania Modesto-Lowe, Lakshit Jain

Mindfulness Training in Opioid Withdrawal

Letter to the Editor

Mindfulness Training in Opioid Withdrawal

June 30, 2022

In this letter to the editor, the authors comment on an article published recently in the PCC.

Vania Modesto-Lowe, Lakshit Jain, Roberto León-Barriera

The Hidden Curriculum in Addiction Training

Letter to the Editor

The Hidden Curriculum in Addiction Training

March 24, 2022

In this letter to the editor, the authors discuss the stigma associated with addiction treatment, as well as strategies to increase addiction literacy among physicians.

Vania Modesto-Lowe, Brian Wasicek

Letter to the Editor

Can You Teach Resilience?

July 27, 2021

This Letter to the Editor comments on two recent Journal articles that discuss coping responses and resilience among health care workers during the COVID-19 pandemic.

Vania Modesto-Lowe, Joseph C. LaBell, Natalie Z. Meyers